招银证券：给予和黄医药(00013.HK)“增持”评级 目标价35.67港元

(资料图片)

招银证券8月2日发布公告。Maintain BUY. We are positive about the FDA/EMA approvals of fruquintinib in late2023. We revised our TP from HK$37.49to HK$35.67based on DCF valuation (WACC:10.25%, terminal growth rate:3.0%).